North Carolina’s State Employee Health Plan Ends Coverage Of GLP-1 Drugs For Weight Loss Due To Cost Concerns
The North Carolina State Health Plan that covers 750,000 state employees and teachers ended coverage of glucagon-like peptide-1 (GLP-1) drugs for the purpose of weight loss (brand names Saxenda, Wegovy, and Zepbound), effective April 1, 2024. The coverage change does not affect members using the medications as treatment to manage Type 2 diabetes. GLP-1 agonists are drugs that mimic the effects of the natural GLP-1 hormone, which regulates blood sugar and appetite.
Initially, the plan's Board of Trustees had enacted a coverage moratorium at its October 26, 2023 meeting. The moratorium was on . . .